ZD-1839 |
IRESSA |
GEFITINIB |
N-(3-CHLORO-4-FLUOROPHENYL)-7-METHOXY-6-(3-(4-MORPHOLINYL)PROPOXY)-4-QUINAZOLINAMINE |
IRESSA® |
ZD1839 |
ZD 1839 |
4-(3'-CHLORO-4'-FLUOROANILINO)-7-METHOXY-6-(3-MORPHOLINOPROPOXY)QUINAZOLINE |
rxcui:328134 |
chemidplus:184475-35-2 |
drugbank:00317 |
pubchem.compound:123631 |
chembl:CHEMBL939 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2003 |
FDA Approval | Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations) |
Drug Class | Kinase Inhibitors |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | quinazolines |
Drug Categories | tyrosine kinase inhibitors |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction? | True |
Direct Interaction? | False |
Endogenous Drug? | False |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
n/a |
combination therapy | Gefitinib + Linsitinib |
Indication/Tumor Type | glioblastoma multiforme |
Response Type | sensitive |
GEFITINIB | DrugBank Drug Name |
184475-35-2 | CAS Number |
Apo-gefitinib | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
GEFITINIB | Primary Drug Name |
Year of Approval | 2003 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
ZD1839 | Development Name |
GEFITINIB | Generic Name |
IRESSA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations) |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
C1855 | NCI drug code |
CHEMBL939 | ChEMBL Drug ID |
C1855 | NCI drug code |
ZD1839 | Drug Trade Name |
GEFITINIB | GuideToPharmacology Ligand Name |
D01RYO | TTD Drug ID |
D09XZB | TTD Drug ID |